← Leaderboards
Matthew R Grimmer
University Of California, San Francisco
$139,037
Attributed
$139,037
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $56.3K · FY2016–18$100K$75K$50K$25K$0
'16
'17
'18
Funding mix
By agency
NIH$139,037 · 1
By mechanism
F32$139,037 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Sabrina Miriam Ronen$18,398,578
- Daniel B Vigneron$43,424,992
- Deepak Ashok Lamba$4,257,564
- Pavithra Viswanath$6,465,079
- Claudia Katharina Petritsch$3,588,663
Others in their field
Top investigators on “Adjuvant Therapy”
- Lawrence Corey · Fred Hutchinson Cancer Center$265,384,749
- Norman Wolmark · Nsabp Foundation, Inc.$252,082,455
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$105,968,129
- David Heimbrook · Leidos Biomedical Research, Inc.$59,661,099
- Dan H. Barouch · Fred Hutchinson Cancer Center$58,263,037
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$58,263,037
Research focus
Adjuvant TherapyActionable MutationAlkylating AgentsAneuploidyAstrocytomaAlgorithmsAutomobile DrivingCell LineCellsChip-SeqChromatinChromatin Remodeling FactorClinical PracticeClone CellsCohortCytotoxicData SetDna LesionDna RepairEndonuclease IEngineeringEpigenetic ProcessEpigenomeEpigenomics
Grant awards (3)
Hypermutation and malignant progression in an expanded cohort of TMZ treated LGG patients from different molecular subgroups$26,585
F32 · FY2018 · CA · contact PI
Hypermutation and malignant progression in an expanded cohort of TMZ treated LGG patients from different molecular subgroups$56,334
F32 · FY2017 · CA · contact PI
Hypermutation and malignant progression in an expanded cohort of TMZ treated LGG patients from different molecular subgroups$56,118
F32 · FY2016 · CA · contact PI